Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 17, Morgan Stanley upgraded FOLD to Overweight with a $12 price target, citing its strong intellectual property position ahead of a key legal decision with Aurobindo.

Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion

A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab.

The firm also pointed to Amicus’s solid financials—including a 90.6% gross margin and a current ratio of 3.34—and growing confidence in patient shifts toward PomOp over Nexviazyme/Lumizyme.

Morgan Stanley adjusted its sales forecasts slightly below consensus for Galafold and PomOp, but remains bullish due to Amicus’s recent licensing of DMX-200 for FSGS treatment. With strategic supply chain planning and U.S. inventory in place, management expects minimal tariff impact in 2025, reinforcing the company’s operational resilience.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a global biotechnology company that develops and delivers transformative medicines for people living with rare metabolic diseases. It leverages innovative technology platforms to create treatments for genetic diseases, with a strong emphasis on patient needs.

While we acknowledge the potential of FOLD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than FOLD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Airline Stocks to Buy According to Hedge Funds and Goldman Sachs REIT Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.